$6.27
2.64% today
Nasdaq, Sep 16, 08:19 pm CET
ISIN
US12529R1077
Symbol
CCCC
Sector
Industry

C4 Therapeutics Inc Stock price

$6.44
+0.74 12.98% 1M
-4.29 39.98% 6M
+0.79 13.98% YTD
+4.13 178.79% 1Y
-43.31 87.06% 3Y
-12.56 66.11% 5Y
-12.56 66.11% 10Y
Nasdaq, Closing price Fri, Sep 13 2024
+0.03 0.47%
ISIN
US12529R1077
Symbol
CCCC
Sector
Industry

Key metrics

Market capitalization $446.53m
Enterprise Value $250.85m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 8.54
P/S ratio (TTM) P/S ratio 15.20
P/B ratio (TTM) P/B ratio 1.79
Revenue growth (TTM) Revenue growth 83.26%
Revenue (TTM) Revenue $29.38m
EBIT (operating result TTM) EBIT $-116.46m
Free Cash Flow (TTM) Free Cash Flow $-78.76m
Cash position $264.10m
EPS (TTM) EPS $-1.90
P/E forward negative
P/S forward 15.71
EV/Sales forward 8.82
Short interest 20.40%
Show more

Is C4 Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

C4 Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a C4 Therapeutics Inc forecast:

5x Buy
63%
3x Hold
38%

Analyst Opinions

8 Analysts have issued a C4 Therapeutics Inc forecast:

Buy
63%
Hold
38%

Financial data from C4 Therapeutics Inc

Jun '24
+/-
%
Net Profit -108 -108
23% 23%
-367%
Depreciation and Amortization 7.76 7.76
3% 3%
26%
Stock Compensation 27 27
6% 6%
92%
Operating Cash Flow -78 -78
29% 29%
-265%
Investments 0.95 0.95
83% 83%
3%
Dividend Paid - -
-
-
Free Cash Flow -79 -79
32% 32%
-268%

In millions USD.

Don't miss a Thing! We will send you all news about C4 Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

C4 Therapeutics Inc Stock News

Neutral
GlobeNewsWire
3 days ago
CFT1946 Is Well-Tolerated at All Dose Levels; No Dose-Limiting Toxicities CFT1946 Achieves Dose Proportional Pharmacokinetic Exposure; Successfully Degrades BRAF V600 Mutant Protein Early Evidence of CFT1946 Monotherapy Anti-Tumor Activity in Patients Who Have Progressed on or After BRAF Inhibitor Therapies; Majority of Patients Demonstrated Tumor Reduction Across V600 Mutation Types CFT1946 Gl...
Neutral
GlobeNewsWire
8 days ago
Abstract Released Today Highlights Favorable Safety Profile and Early Evidence of Monotherapy Anti-Tumor Activity Investor Webcast to be Held Friday, September 13, 2024 at 12:00 pm ET WATERTOWN, Mass., Sept. 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announ...
Neutral
GlobeNewsWire
13 days ago
WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Stephen (Steve) Fawell, Ph.D. as a director. With this appointment, Malcolm Salter has decided to retire f...
More C4 Therapeutics Inc News

Company Profile

C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Andrew Hirsch
Employees 145
Founded 2015
Website www.c4therapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today